Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) EPS (Weighted Average and Diluted) (2020 - 2025)

Maxcyte (MXCT) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.12 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 9.09% to -$0.12 in Q3 2025 year-over-year; TTM through Sep 2025 was -$0.38, a 2.7% decrease, with the full-year FY2024 number at -$0.39, down 5.41% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.12 for Q3 2025 at Maxcyte, down from -$0.12 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.03 in Q3 2021 to a low of -$0.12 in Q3 2025.
  • A 5-year average of -$0.08 and a median of -$0.09 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 55.56% in 2022, then plummeted 175.0% in 2023.
  • Maxcyte's EPS (Weighted Average and Diluted) stood at -$0.05 in 2021, then decreased by 0.0% to -$0.05 in 2022, then grew by 0.0% to -$0.05 in 2023, then tumbled by 100.0% to -$0.1 in 2024, then fell by 20.0% to -$0.12 in 2025.
  • Per Business Quant, the three most recent readings for MXCT's EPS (Weighted Average and Diluted) are -$0.12 (Q3 2025), -$0.12 (Q2 2025), and -$0.1 (Q1 2025).